BCAX
HEALTHCAREBicara Therapeutics Inc
$23.78+0.62 (+2.68%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving BCAX Today?
No stock-specific AI insight has been generated for BCAX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$7.80$24.25
$23.78
Fundamentals
Market Cap$1.6B
P/E Ratio—
EPS$-2.52
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume325K
Avg Volume (10D)—
Shares Outstanding65.6M
BCAX News
20 articles- Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000Motley Fool·May 4, 2026
- Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ETYahoo Finance·May 4, 2026
- A Look At Bicara Therapeutics (BCAX) Valuation After Earnings Losses And New Shelf RegistrationYahoo Finance·Apr 7, 2026
- Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Apr 3, 2026
- Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here's is How to TradeYahoo Finance·Apr 1, 2026
- Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year?Yahoo Finance·Apr 1, 2026
- Morning Movers: Sysco dips following deal to acquire Jetro Restaurant DepotYahoo Finance·Mar 31, 2026
- Bicara Therapeutics Inc. Common Stock Q4 2025 Earnings Call SummaryMoby·Mar 31, 2026
- Bicara Therapeutics Inc (BCAX) Q4 2025 Earnings Call Highlights: Strong Cash Position and ...Yahoo Finance·Mar 30, 2026
- Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy?Motley Fool·Mar 30, 2026
- Bicara Therapeutics Q4 Earnings Call HighlightsMarketbeat·Mar 30, 2026
- Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 30, 2026
- Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder.Motley Fool·Mar 26, 2026
- Bicara gains buy rating as BofA sees SoC potential in cancer drug FiceraProactive Investors·Mar 25, 2026
- Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ETYahoo Finance·Mar 23, 2026
- Bicara Therapeutics Talks Ficerasfusp Alfa Data, Pivotal Trial Timeline and $172M Raise at ConferenceMarketbeat·Mar 13, 2026
- A Look At Bicara Therapeutics (BCAX) Valuation After New FICERA Clinical Data And Accelerated Approval PlanYahoo Finance·Mar 7, 2026
- Bicara Therapeutics Touts FICERA Data, Sets Pivotal FORTIFY Path at TD Cowen ConferenceMarketbeat·Mar 6, 2026
- Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesYahoo Finance·Feb 26, 2026
- Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·Feb 25, 2026
All 20 articles loaded
Price Data
Open$23.24
Previous Close$23.16
Day High$23.80
Day Low$22.82
52 Week High$24.25
52 Week Low$7.80
52-Week Range
$7.80$24.25
$23.78
Fundamentals
Market Cap$1.6B
P/E Ratio—
EPS$-2.52
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume325K
Avg Volume (10D)—
Shares Outstanding65.6M
About Bicara Therapeutics Inc
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. The company is headquartered in Boston, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—